Overview

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsenon the quality and pattern of HAE attacks and their impact on quality of life (QoL).
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.